About: A high-throughput inhibition assay to study MERS-CoV antibody interactions using image cytometry

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A high-throughput inhibition assay to study MERS-CoV antibody interactions using image cytometry Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	A high-throughput inhibition assay to study MERS-CoV antibody interactions using image cytometry
Creator	Zhang, Yi Shi, Wei Wang, Nianshuang Kong, Wing-Pui Wang, Lingshu Abiona, Olubukola Corbett, Kizzmekia Graham, Barney Mclellan, Jason Rosen, Osnat Chan, -Ying Gough, Portia Li, Leo
Source	Elsevier; Medline; PMC
abstract	Abstract The emergence of new pathogens, such as Middle East respiratory syndrome coronavirus (MERS-CoV), poses serious challenges to global public health and highlights the urgent need for methods to rapidly identify and characterize potential therapeutic or prevention options, such as neutralizing antibodies. Spike (S) proteins are present on the surface of MERS-CoV virions and mediate viral entry. S is the primary target for MERS-CoV vaccine and antibody development, and it has become increasingly important to understand MERS-CoV antibody binding specificity and function. Commonly used serological methods like ELISA, biolayer interferometry, and flow cytometry are informative, but limited. Here, we demonstrate a high-throughput protein binding inhibition assay using image cytometry. The image cytometry-based high-throughput screening method was developed by selecting a cell type with high DPP4 expression and defining optimal seeding density and protein binding conditions. The ability of monoclonal antibodies to inhibit MERS-CoV S binding was then tested. Binding inhibition results were comparable with those described in previous literature for MERS-CoV spike monomer and showed similar patterns as neutralization results. The coefficient of variation (CV) of our cell-based assay was <10%. The proposed image cytometry method provides an efficient approach for characterizing potential therapeutic antibodies for combating MERS-CoV that compares favorably with current methods. The ability to rapidly determine direct antibody binding to host cells in a high-throughput manner can be applied to study other pathogen-antibody interactions and thus can impact future research on viral pathogens.
has issue date	2019-03-31(xsd:dateTime)
bibo:doi	10.1016/j.jviromet.2018.11.009
bibo:pmid	30468747
has license	els-covid
sha1sum (hex)	f894f55b27a073407a13bad1c2f247df1a2d9cc1
schema:url	https://doi.org/10.1016/j.jviromet.2018.11.009
resource representing a document's title	A high-throughput inhibition assay to study MERS-CoV antibody interactions using image cytometry
has PubMed Central identifier	PMC6357230
has PubMed identifier	30468747
schema:publication	Journal of Virological Methods
resource representing a document's body	covid:f894f55b27a073407a13bad1c2f247df1a2d9cc1#body_text
is schema:about of	named entity 'MERS-COV' named entity 'antibody' named entity 'binding' named entity 'high-throughput' named entity 'However' named entity 'primary' named entity 'The' named entity '2015' named entity 'binding' named entity 'direct' named entity 'The' named entity 'monoclonal antibodies' named entity 'inhibit' named entity 'assay' named entity '2017' named entity 'The' named entity 'MERS-CoV' named entity 'host' named entity 'interactions' named entity 'ABILITY TO' named entity 'USING' named entity 'LITERATURE' named entity 'SPECIFIC' named entity 'HERE' named entity 'ASSAY' named entity 'VACCINE' named entity 'COEFFICIENT OF VARIATION' named entity 'NIU' named entity 'FLOW CYTOMETRY' named entity 'BUT' named entity 'SEROLOGICAL' named entity 'CELL TYPE' named entity 'OPTIMAL' named entity 'INFORMATIVE' named entity 'THERAPEUTIC ANTIBODIES' named entity 'IDENTIFY' named entity 'SPIKE' named entity 'PATTERNS' named entity 'INTERFEROMETRY' named entity 'IMAGE CYTOMETRY' named entity 'NEUTRALIZING ANTIBODIES' named entity 'ELISA' named entity 'VIRIONS' named entity 'RAPIDLY' named entity 'PUBLICATIONS' named entity 'METHODS' named entity '2015' named entity 'INHIBITION' named entity 'PREVENTION' named entity 'HOST CELLS' named entity 'BINDING' named entity 'URGENT' named entity 'THERAPEUTIC' named entity 'SELECTING' named entity 'UNDERSTAND' named entity 'ANTIBODY' named entity 'APPLIED' named entity 'HAVE' named entity 'DENSITY' named entity 'IMAGE CYTOMETRY' named entity 'EFFICIENT' named entity 'TO INHIBIT' named entity 'DPP4' named entity 'DEFINING' named entity 'PROTEINS' named entity 'USED' named entity 'EXPRESSION' named entity 'PATHOGEN' named entity 'INHIBITION'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software